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Abstract: Human T lymphotropic viruses (HTLVs) are complex deltaretroviruses that do 
not contain a proto-oncogene in their genome, yet are capable of transforming primary  
T lymphocytes both in vitro and in vivo. There are four known strains of HTLV including 
HTLV type 1 (HTLV-1), HTLV-2, HTLV-3 and HTLV-4. HTLV-1 is primarily associated 
with adult T cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP). HTLV-2 is rarely pathogenic and is sporadically associated with 
neurological disorders. There have been no diseases associated with HTLV-3 or HTLV-4 
to date. Due to the difference in the disease manifestation between HTLV-1 and HTLV-2, 
a clear understanding of their individual pathobiologies and the role of various viral 
proteins in transformation should provide insights into better prognosis and prevention 
strategies. In this review, we aim to summarize the data accumulated so far in the 
transformation and pathogenesis of HTLV-1, focusing on the viral Tax and HBZ and citing 
appropriate comparisons to HTLV-2. 
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1. General Background and Overview 
Human T lymphotropic virus type 1 (HTLV-1) is a complex leukemogenic retrovirus with a single 
stranded positive sense RNA genome that expresses unique proteins with oncogenic potential. There 
are four known strains of HTLV, of which HTLV-1 and HTLV-2 are the most prevalent worldwide. 
HTLV-1 was originally identified in 1980 in a T cell line derived from a patient with cutaneous T cell 
lymphoma [1] and was also detected in adult T cell leukemia (ATL) patients [2,3]. Subsequently, 
HTLV-2 was identified in a cell line derived from a patient with a variant form of hairy T cell 
leukemia [4-6]. Since then, HTLV-2 has not been associated with leukemia/lymphoma; nevertheless, it 
has been associated with a few sporadic cases of neurological disorders [7]. HTLV-1 can infect   
T cells, B cells, monocytes, dendritic cells and endothelial cells with equal efficiency; yet, it can 
transform only primary T cells [8-11].  
HTLV-1 is an enveloped virus that is approximately 100 nm in diameter. The inner membrane of 
the virion envelope is lined by the viral matrix protein (MA). This structure encloses the viral capsid 
(CA), which carries two identical strands of the genomic RNA as well as functional protease (Pro), 
integrase (IN), and reverse transcriptase (RT) enzymes. A newly synthesized viral particle attaches to 
the target cell receptor through the viral envelope (Env) and enters via fusion, which is followed by the 
uncoating of the capsid and the release of its contents into the cell cytoplasm. The viral RNA is reverse 
transcribed into double stranded DNA by the RT. This double stranded DNA is then transported to the 
nucleus and becomes integrated into the host chromosome forming the provirus. The provirus contains 
the promoter and enhancer elements for transcription initiation in the long terminal repeats (LTR); the 
polyadenylation signal for plus strand transcription is located in the 3ʹLTR [1].  
HTLV-1 is dependent on cellular factors for the initial rounds of transcription. The complex 
retroviral genome codes for the structural proteins Gag (capsid, nucleocapsid, matrix), Pro, polymerase 
(Pol) and Env from unspliced/singly spliced mRNAs [12-14] and regulatory and accessory proteins 
from alternatively spliced mRNA transcripts (Figure 1). The two regulatory genes tax and rex are 
encoded by open reading frames (ORF) IV and III, respectively, and share a common doubly spliced 
transcript. Tax is the transactivator gene, which increases the rate of viral LTR-mediated transcription 
[15-17] and modulates the transcription of numerous cellular genes involved in cell proliferation and 
differentiation, cell cycle control and DNA repair [18-23]. Tax has displayed oncogenic potential in 
several experimental systems [24-28] and is essential for HTLV-1 and HTLV-2-mediated 
transformation of primary human T cells [29-31]. Rex acts post-transcriptionally by preferentially 
binding, stabilizing and selectively exporting intron-containing viral mRNAs from the nucleus to the 
cytoplasm [32]. The accessory genes, p12/p8 encoded by ORF I and p30/p13 encoded by ORF II are 
dispensable in standard immortalization assays in culture but are essential for initiation of viral 
infection and the establishment of persistence in animal models [33-36]. p8 is a proteolytic cleavage 
product of the p12 parent molecule, whereas the p13 polypeptide, comprised of the carboxy terminus 
of p30, is expressed from a distinct mRNA. These accessory proteins may also play a role in gene 
regulation and contribute to the productive infection of quiescent T lymphocytes in vitro [37-40]. The 
minus strand of the proviral genome encodes several isoforms (generated from unspliced and spliced 
mRNAs) of the HTLV-1 basic leucine zipper factor (HBZ) [41]. HBZ interacts with cellular factors 
JunB, c-Jun, JunD, cAMP response element binding (CREB) and CREB binding protein (CBP)/p300 Viruses 2010, 2                  
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to modulate both viral and cellular gene transcription [42-44]. HBZ also plays a crucial role in T cell 
proliferation [45-47]. Among all the viral proteins, experimental evidence implicates Tax as the viral 
oncoprotein, but emerging data suggests a supporting role for HBZ in the oncogenic process. 
Figure 1. Structure of the HTLV-1 proviral genome and gene product key functions. The 
proviral DNA with the LTRs, and the unspliced, singly spliced and doubly spliced mRNA 
transcripts are shown to scale. The names of the gene transcripts are depicted inside each 
specific box (protein coding sequence). Solid lines indicate the exons and the dotted lines 
indicate the introns. Splice donor sites are indicated by open arrows and major splice 
acceptor sites are indicated by closed arrows. The numbers represent the nucleotide 
positions relative to the viral RNA. The general key functions for each of the genes at the 
protein level are listed to the right (see text for detail). 
 
 
2. Disease Association 
HTLV-1 predominantly causes ATL and HTLV-1-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP). There are five different clinical stages of ATL: asymptomatic carrier state, 
preleukemic state, chronic/smoldering ATL, lymphoma type and acute ATL [48-51]. The majority of 
the HTLV-1 infected patients are asymptomatic carriers who do not show any clinical symptoms. Even 
in the absence of symptoms, these individuals are capable of transmitting the virus to others. 
Approximately 1-2% of asymptomatic carriers progress to ATL over a 20-40 year period. HTLV-1 is 
less commonly associated with other disease conditions such as B cell chronic lymphocytic leukemia 
[52], chronic inflammatory arthropathy [53-55], HTLV-1 associated uveitis [56,57], T cell non-
Hodgkin’s lymphoma [58,59], T-prolymphocytic leukemia, Sezary’s syndrome, small cell carcinoma, Viruses 2010, 2                  
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large granular lymphocytic leukemia (T-gamma lymphoproliferative disease) [60,61], dermatitis, 
lymphadenitis and Sjogren’s syndrome [62].  
Although HTLV-2 initially was identified in a CD8
+ T cell line derived from a patient with a variant 
form of hairy cell leukemia [4-6], there have been no subsequent reports of HTLV-2-associated 
neoplasms. However, there have been sporadic reports of HTLV-2-associated chronic 
encephalomyelopathy. The clinical symptoms presented are similar to those of HAM/TSP [63]. The 
prevalence of HTLV-2-associated myelopathy was reported to be 1% compared to 3.7% for HAM/TSP 
[64]. Although other neurological disorders have been reported, their clear association with HTLV-2 is 
hampered by confounding factors such as intravenous drug use or concomitant HIV infection [63]. To 
date, HTLV-3 and HTLV-4 have not been associated with any known clinical conditions.  
3. Epidemiology 
Approximately 15-25 million people worldwide are infected with HTLV-1 [62,65]. The virus is 
endemic in southwestern Japan [66], Africa [67,68], the Caribbean Islands [69] and South America 
[70] and is frequently found in Melanesia, Papua New Guinea [71], Solomon Islands and Australian 
aborigines [62]. HTLV-1 also is prevalent in certain populations in the Middle East [72] and India 
[73,74]. Of HTLV-1 infected patients, only 6.6% of males and 2.1% of females develop ATL [62]. 
HTLV-2 is more prevalent among intravenous drug users (IDUs), and is endemic among IDUs in the 
USA [75], Europe [76], South America [77] and southeast Asia [78]. HTLV-3 and HTLV-4 have been 
identified only in African primate hunters [79,80]. 
4. Viral transmission 
Of the many possible routes of virus transmission, mother-to-child through breast feeding is the 
most predominant mode [81]. Transmission rates are 16% for children born to infected mothers, 27% 
for children nursed by infected mothers for more than three months and 5% for children nursed by 
infected mothers for less than three months [82,83]. Interestingly, about 13% of bottle-fed children 
also contract HTLV from their infected mother suggesting a route other than breast-feeding. The 
infants seroconvert within 1-3 years of age [83,84]. Sexual transmission rates are 60% for male to 
female, but only 0.4% for female to male transmission [85-87]. Predisposing factors associated with 
sexual transmission include the presence of genital ulcers, high viral loads and high antibody titers in 
the donor [86,87]. Among non-drug using sexual partners of IDUs, sexual transmission is a more 
common mode then parenteral transmission [88]. Among IDUs, blood and blood products are the most 
significant source of infection [89]. Approximately 12% of HTLV infections occur by blood 
transfusion. Unlike HIV-1, whole cell transfusion is required for transmission of the virus [90,91], with 
a seroconversion rate of approximately 50% [90,92]; however, the risk of transmission decreases 
markedly if the blood units are stored for more than six days before transfusion [91,93]. The 
development of HAM/TSP has been noted as early as six months after transfusion of an individual 
with infected blood [94]. In 1988, concerns about transmission of HTLV through blood components 
led to mandatory blood donor screening for HTLV resulting in a significant decrease in transmission 
via this mode.  
Cell-free infection with HTLV-1 is very inefficient [95]; efficient transmission depends on cell-to-Viruses 2010, 2                  
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cell transfer through direct cell contact, polarization of the microtubule-organizing center (MTOC), 
which is triggered by Tax, and the formation of a virological synapse, which allows the entry of viral 
particles, viral proteins and genomic RNA into fresh target cells [96]. As with HIV-1 infection, 
dendritic cells (DCs) have been demonstrated to play a biphasic role in cell-to-cell transmission of 
HTLV-1. DCs can capture and transfer the virions to fresh T cells in a trans fashion or transmit de 
novo synthesized virions upon infection to fresh T cells in a cis fashion [97]. 
5. Viral persistence 
Only about 1% of asymptomatic carriers progress to ATL, which occurs after about 2-4 decades of 
clinical latency. On the contrary, for HAM/TSP, disease progression can typically occur within a few 
years of infection [94,98]. In either case, the virus has co-evolved with its host to maintain lifelong 
persistence with an occasional exacerbation of pathological manifestations. HTLV-1 regulatory and 
accessory proteins, Rex, p12 and p30/p13 have been implicated to play a role in viral persistence. 
During the initial stage of infection, translation of Tax is favored over Rex due to a stronger Kozak 
sequence. Thus, the insufficient translation of Rex results in the export of only the doubly or 
completely spliced viral mRNAs, due to default splicing by the host cell machinery [99]. Eventually, 
accumulation of sufficient levels of Rex results in the expression of incompletely spliced mRNA in the 
cytoplasm, leading to the production of structural and enzymatic gene products and assembly of virus 
particles. Therefore, Rex is considered a positive regulator that controls the switch between 
early/latent and late/productive infection, which may help the virus avoid immune surveillance   
[32,99-101]. The expression of an accessory protein, p30, results in activation of the G2-M cell cycle 
checkpoint in Jurkat T cells, which suggests that p30 is involved in events that would promote early 
viral spread and T cell survival [102]. p30 also binds and retains doubly spliced tax/rex mRNA 
transcripts in the nucleus, thereby repressing viral gene expression and facilitating immune evasion 
[38,103]. Although p30 is dispensable for HTLV-1-mediated cellular transformation in cell culture, 
inoculation of rabbits with a p30-deficient virus revealed that p30 expression is required early in 
infection to sustain high viral loads and promote persistence in rabbits [33]. A recent report could not 
confirm the p30 ablation phenotype in HTLV-1 infected rabbits, but revealed its importance in viral 
persistence in macaques [36]. Thus, Rex is a positive post-transcriptional regulator, while p30 is a 
negative post-transcriptional regulator. Both viral proteins are maintained in a feedback loop to 
promote viral persistence and evasion of the host immune pressure [104].  
A second accessory protein, p12, accumulates in the endoplasmic reticulum (ER) and Golgi 
compartments [105-107]. p12 interacts with interleukin-2 receptor β (IL-2Rβ) and IL-2R chains 
leading to activation of the Janus kinase/signal transducer and activator of transcription 5 (Jak/Stat5) 
signal transduction pathway, and is required for efficient infection of quiescent primary T cells and 
syncytium formation [37,108-110]. The mechanisms by which p12 promotes immune evasion include 
interference with the presentation of major histocompatibility complex I (MHC class I) molecules by 
inducing the proteasomal degradation of the newly synthesized MHC molecules [107] and recruitment 
of p8 (the proteolytic cleavage product of p12 that facilitates the trafficking of the protein from the ER 
to the cell surface through the Golgi apparatus) to the virological synapse to down-regulate proximal 
signaling [40,111-113]. Another in vitro study demonstrated that p12 promoted cell-to-cell spread by Viruses 2010, 2                  
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inducing lymphocyte function-associated antigen 1 (LFA-1) clustering on T cells via calcium-
dependent signaling [114]. In vivo animal models have established an essential role for p12 in 
persistent viral infection [34,36]. Valeri et al. have suggested that the lack of viral persistence of  
p12-deficient HTLV-1 in macaques is due to the inability of these viruses to efficiently infect   
DCs [36]. In the context of an infectious molecular clone, a third accessory protein, p13, was 
demonstrated to be dispensable for HTLV-1 infection and immortalization of primary T cells in culture 
[115]; whereas rabbits inoculated with a p13-deficient virus failed to induce a significant immune 
response and establish a persistent infection [116]. p13 mainly localizes in the mitochondria and 
suppresses tumor growth by interfering with Ras and Myc oncogenes [117,118]. Although p13 
expression is not an apoptotic signal by itself, it sensitizes the cell to FasL and C-2 ceramide-induced 
apoptosis [118,119]. p13
 
alters the mitochondrial morphology by disrupting the inner membrane 
potential and calcium ion flux, and binds farnesyl pyrophosphate synthetase, an enzyme involved in 
post-translational prenylation of Ras [120]. Since Tax and p13 have opposing effects on apoptosis, the 
virus balances their functions to achieve two different scenarios. The first is to maintain a balance 
between the expression levels of Tax and p13 in order to regulate cell survival and proliferation of the 
infected cells leading to viral persistence. The second is to promote a cooperative effect, where p13 
initially increases reactive oxygen species (ROS) in the mitochondria, which increases genetic 
instability or apoptosis in cells. Then, Tax promotes the selective growth and survival of these 
genetically unstable cells leading to the accumulation of DNA damage and progression towards 
neoplastic development [121]. 
6. Viral Transformation 
Although HTLV-1 and HTLV-2 display differences in pathogenicity, both viruses can transform 
primary human T cells in cell culture. The precise mechanism by which these viruses transform T cells 
is not fully understood; however, a number of viral proteins have been implicated to play a role in 
HTLV- induced T cell transformation and pathogenesis. HTLV-1 and HTLV-2 exhibit differences in 
transformation tropism, where HTLV-1 preferentially transforms CD4
+ T cells both in vitro and in vivo 
while HTLV-2 transforms CD8
+ T cells in in vitro co-culture assays [122-125]. Tax-mediated 
transcription of HTLV-1 is significantly increased in CD4
+ T cells as compared to CD8
+ T cells, but 
the viral burden is higher in the latter [126,127]. The in vivo tropism of HTLV-2 appears to be less 
clear. Although Ijichi et al. have shown that HTLV-2 has a preferential tropism for CD8
+ T cells in 
vivo [128], unlike HTLV-1, both CD4
+ T cells and CD8
+ T cells are equally susceptible to HTLV-2 
infection and subsequent viral gene expression, with a greater proviral burden observed in CD8
+ T 
cells [123,124,129]. In a quest to find the genetic determinant responsible for this differential 
transformation tropism, the first HTLV-1/2 recombinant viruses were generated and tested. 
Unexpectedly, results revealed that neither Tax nor the viral LTR sequences played a role [125,130]. 
Indeed, it was the viral envelope that conferred this distinct transformation tropism [130]. The viral 
envelope has two glycoproteins, surface component (SU) and transmembrane component (TM). SU 
binds to the cellular receptor, while TM triggers the fusion of the viral and cellular membranes, 
facilitating viral entry. Binding studies have supported the role of viral envelope in the distinct 
transformation tropism by showing that HTLV-1 binds to heparin sulfate proteoglycans (HSPG) on Viruses 2010, 2                  
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CD4
+ T cells, while HTLV-2 binds to glucose transporter 1 (GLUT-1) on CD8
+ T cells [131].  
The viral transactivator protein, Tax, and the minus strand-encoded HBZ have been shown to play 
an essential role in HTLV-1 induced oncogenesis. Tax-induced activation of the nuclear factor B 
(NF-B) pathway [30] and the constitutive activation of the Jak/Stat pathway [132], and HBZ-induced 
activation or regulation of cellular factors like E2F1, JunB, c-Jun, JunD, CREB and CBP/p300 [112] 
have been implicated in transformation. The roles of Tax and HBZ in the induction of transformation 
are discussed in detail below. In addition, the accessory protein, p12, is also a modulator of T cell 
proliferation and immune function. p12 interacts with the 16 kDa subunit of the vacuolar ATPase, a 
complex important for the function of lysosomes and endosomes, and is implicated in transformation 
pathways [133,134]. Furthermore, p12 augments Ca
2+ release from the ER via its ability to bind with 
calnexin and calreticulin, which regulate storage and release of Ca
2+ from the ER, as well as with 
calcineurin, a calcium/calmodulin-dependent phosphatase, resulting in the activation of Nuclear Factor 
of Activated T Cells (NFAT). NFAT has a role in integrating calcium signaling with other signaling 
mechanisms in T cells [135-138]. Although p12 has been associated with proliferation, studies 
utilizing an infectious molecular clone indicated that abrogation of p12 message or protein had no 
effect on viral replication and immortalization of primary T cells in vitro [115].  
7. Viral pathogenesis 
The pathogenesis of ATL involves four stages: infection, polyclonal proliferation, clinical latency 
and tumorigenesis. HTLV-1 infects activated and dividing T cells with greater efficiency than 
quiescent T cells [139]. Env facilitates binding and entry into target cells. T cells become stimulated, 
which may be mediated by CD2/LFA-3, LFA-1/intracellular adhesion molecule (ICAM) and   
IL-2/IL-2R [140]. The activated T cells then form a pool of proliferating lymphoblasts. At this stage, 
the polyclonal population of cells is not leukemic. Indefinite T cell growth occurs in HTLV-1 infected 
individuals, but disease onset is seen only in a small percentage of these individuals. Tax and HBZ 
play a crucial role in the cell alteration process by triggering changes in a variety of intracellular signal 
transduction pathways, both by up-regulating and down-regulating viral and cellular gene expression 
in order to initiate neoplastic transformation [141,142]. The subsequent proliferation of the 
transformed T cells becomes IL-2 independent, which correlates with constitutive activation of the 
Jak/Stat pathways as well as decreased expression of src homology 2 (SH2)-containing tyrosine 
phosphatase-1 (SHP-1) protein, which regulates signaling from several hematopoietic surface 
receptors [143,144]. This transition usually correlates with significantly more rapid disease 
progression [145]. Upon infection of T cells, a period of clinical latency is observed in HTLV-1 
carriers, which usually lasts 20 to 40 years. During this period, the viral genes are expressed at sub-
detectable levels to evade immune surveillance. HTLV-1 undergoes epigenetic silencing and also 
promotes chromosomal aberrations, leading to selection and evolution of monoclonal tumor 
populations. The degree of cytogenetic aberration is directly proportional to disease severity. The 
transactivation of proto-oncogenes such as c-fos,  egr-1 and egr-2 by Tax may also contribute to 
leukemogenesis [146]. The development of tumors delineates the end of clinical latency and 
development of ATL in these patients.  
Several animal models have been used to study HTLV-1 infection, persistence, and to some extent Viruses 2010, 2                  
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disease progression, although so far, these animal models have not been able to successfully mimic 
human ATL. To date, rabbits [147,148], rats [149,150], mice and non-human primates have been used 
as experimental models. Rabbits have been used more extensively because of ease of handling and 
development of a consistent infection that mimics the asymptomatic infection in humans. Although 
rabbits provide a good infection model, they are less helpful as tumorigenic models because they do 
not develop disease [151-155]. Certain strains of rats have been used to study HAM/TSP, although the 
neurodegenerative lesions are not very similar to those of humans. Results using rat models also suffer 
from variability depending on the rat strain employed [149,150]. Furthermore, in order to study 
tumorigenesis, the rats need to be immunodeficient [156]. Some non-human primates like Cynomolgus 
macaques and squirrel monkeys have been tested as animal models. Although these animals 
seroconvert variably, there are no typical signs of clinical disease [36,157,158]. Even though some 
investigators may argue that this subclinical state could mimic the human asymptomatic phase, the 
debate continues as to whether these models will mimic ATL if animals are maintained for longer 
periods; the long waiting time for such experiments make them unappealing. Lastly are the mouse 
models, where both xenograft and transgenic models have been utilized. Genetically normal and 
immunocompetent mice are not efficiently infected with HTLV-1 and they do not develop a natural 
course of illness. However, histologic analysis of xenograft models has shown ATL cells in various 
organs depending on the inoculation route. In addition, biochemical characteristics typical to HTLV-1 
infection of humans including parathyroid hormone related protein (PTHrP) expression and increased 
serum IL-2R and β2-microglobulin levels correspond to increasing tumor burden in these   
mice [159-167]. Transgenic mice provide a good model to test the role of individual HTLV-1 genes in 
the pathogenesis of ATL. They also help in understanding the underlying relationship between the 
viral genes and their ability to cause unregulated cell growth [26,168-174]. The biggest caveat in such 
mouse models is the physiological relevance of these findings in the context of a completely active 
immune system. Humanized mouse models that are being used more extensively in HIV research thus 
far have been less attractive for HTLV-1 research because of the prolonged clinical latency period in 
the latter. 
8. Role of Tax in HTLV-1 induced oncogenesis 
Tax, a transactivator protein, triggers a plethora of events like cell signaling, cell cycle regulation 
and interference with checkpoint control and inhibition of DNA repair. Tax is expressed from a doubly 
spliced mRNA transcript. Although Tax shares the same mRNA transcript with Rex, translation of Tax 
is favored over Rex due to a stronger Kozak sequence. Tax made in the cytoplasm is translocated into 
the nucleus, where it binds to its response element and activates viral LTR-mediated transcription.  
8.1. Effect of Tax on transcription factors 
The Tax response element (TxRE) in the unique 3ʹ (U3) region of the 5ʹLTR is a 21-bp triple repeat, 
which contains an octamer motif TGACG(T/A)(C/G)(T/A) that is flanked by a G stretch at the 5ʹend 
and a C stretch at the 3ʹend. This octamer motif is homologous to the cAMP response element (CRE) 
5ʹ-TGACGTCA-3ʹ [175,176]. Tax does not have the specificity to directly bind TxRE DNA in the 
5ʹLTR.  In vitro biochemical studies have shown that Tax interacts with CRE binding/activating Viruses 2010, 2                  
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transcription factors (CREB/ATF) and forms a ternary complex with TxRE [177-183]. All of these 
proteins share common basic residues that facilitate DNA binding and include a basic leucine zipper 
domain (bZIP), which allows homo- and heterodimerization, which in turn is responsible for the 
ternary complex formation [184]. Tax interacts with the bZIP domain of CREB/ATF, enhances its 
dimerization, increases its affinity to the homologous octamer motif in the viral LTR and finally 
stabilizes the ternary complex by directly binding to the GC-rich flanking sequences [185-190]. Tax 
then recruits co-activators like CBP/p300 and p300/CBP-associated factor (P-CAF) for the initiation of 
transcription [191,192]. Tax binds to CREB/ATF and regulates LTR-mediated transactivation both 
positively and negatively. Tax also binds to co-activators of CREB – transducers of regulated CREB 
activity (TORCs), which facilitate the binding of Tax to CREB/ATF in a p300 and CBP-dependent 
manner [193,194]. Through its interactions with CREB/ATF, Tax represses a number of cellular genes 
including p53, cyclin A and c-myb [19,195,196]. Tax also activates promoters under the control of the 
serum responsive factor (SRF) responsive element (SRE) motifs via interactions with transcription 
factors associated with the SRF pathway. The main transcription factor under the transcriptional 
control of SRF is activator protein 1 (AP-1), which is triggered in response to various stimuli including 
cytokines, growth factors, stress signals, and oncogenes. AP-1 is either a homo- or heterodimeric 
complex of Fos (c-Fos, FosB, Fra1 and Fra2) and Jun (c-Jun, JunB and JunD) [146,197]. Moreover, 
Tax binds directly to SRF and to various members of the ternary complex factor (TCF) such as SRF 
accessory protein 1 (Sap1), Elk1, spleen focus forming virus (SFFV) proviral integration oncogene 1 
(Spi1) and Ets1 [198-203]. These interactions increase the binding of SRF to multiple different SRE 
sequences located in the Fos/Jun promoters, thus occupying the CArG box (CC[A/T]6GG); then the 
TCF establishes a protein interaction with an upstream Ets box (GGA[A/T]). Once these complexes 
stabilize, Tax recruits the co-activators CBP/p300 and P-CAF to activate transcription [203]. Thus, 
Tax transactivation from CREB and SRF responsive sites involves its interaction with transcription 
factors by enhancing DNA binding, altered site selection and co-activator recruitment. 
8.2. Tax and T cell transformation 
Apart from activating viral gene transcription, Tax induces various cellular functions in the   
HTLV-1 infected cells and thus, renders them susceptible to viral persistence and thereby initiates 
neoplastic transformation. NF-B is a key player in Tax-induced T cell transformation. The NF-B 
family of transcription factors includes five structurally related members – RelA, RelB, c-Rel, NF-B1 
(p50/p105) and NF-B2 (p52/p100)  [204-206]. The precursor proteins, p105 and p100, are 
proteolytically cleaved to the mature p50 and p52 forms. These proteins form various dimeric 
complexes in the cytoplasm. In naïve T cells, the dimers are trapped by inhibitory IB proteins such as 
p105, p100, IB, IBβ and IB. IBs mask the nuclear localization signal (NLS) of the NF-B 
factors by physical interaction [204,205]. Upon activation of the T cells by an appropriate stimulus, 
IB kinase (IKK) phosphorylates IB inhibitors, thereby triggering their ubiquitination and subsequent 
proteasomal degradation. This event leads to the exposure of the NLS and the eventual translocation of 
the NF-B factors to the nucleus, where they transactivate or repress target genes bearing a B 
enhancer [204,205,207]. The NF-B family plays a crucial role in immune functions such as innate 
and adaptive responses, survival of lymphocytes and lymphoid tissue development [206]. Therefore, 
any aberrant NF-B activation could lead to the genesis of cancer, especially hematologic Viruses 2010, 2                  
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malignancies such as leukemia, lymphoma and myeloma [208]. NF-B functions via two signaling 
pathways – classical and alternate. Both pathways regulate overlapping but distinct cellular genes. The 
classical pathway is activated by inflammatory cytokines, genotoxic stress, antigens and toll-like 
receptor (TLR) stimulation, which results in degradation of IB inhibitor and the translocation of 
p50/RelA complex into the nucleus. The alternate pathway is activated by a subset of tumor necrosis 
factor (TNF) family members such as CD40L, lymphotoxin-β, B cell activating factor belonging to the 
TNF family (BAFF), receptor activator for NF-B ligand (RANKL) and TNF-like weak inducer of 
apoptosis (TWEAK). Activation of the alternate pathway results in the processing of p100/RelB into 
p52/RelB and the translocation of the latter to the nucleus [209].  
In naïve T cells, the activity of NF-B pathways is tightly controlled. NF-B is transiently activated 
upon immune stimulation, but constitutively activated in HTLV-1 infected T cells  [210-213]. 
Constitutive activation of NF-B is mediated by Tax and is essential for the induction of T cell 
transformation. Mechanistically, Tax binds to IKK (NF-B essential modulator, NEMO) and 
activates the IKK complex  [214,215]. Tax also binds to transforming growth factor – β activated 
kinase 1 (TAK1), a mitogen activator protein-3 kinase (MAP3K), and stimulates IKK activity [216]. 
Tax undergoes post-translational modifications including phosphorylation, acetylation, sumoylation 
and ubiquitination [217-223]. Of these, ubiquitination is crucial for binding to NEMO and is 
dependent on E2 ubiquitin-conjugating enzyme, Ubc13 [221]. NEMO-related protein 
(NRP/Optineurin) binds to Tax and positively modulates the ubiquitination of Tax resulting in 
activation of the NF-B pathway [224]. Tax expressed by HTLV-1 activates both the classical and 
alternate pathways of NF-B by binding simultaneously to the IKK complex and NF-B2/p100 
leading to IKK-mediated p100 phosphorylation and its subsequent cleavage into p52 [225]. HTLV-2 
Tax can activate the classical pathway at levels comparable to that of HTLV-1 Tax, but cannot activate 
the alternate pathway because the former cannot interact with p100 [226]. Dependence on NF-B 
activation by Tax for the immortalization of T cells both in vitro and in vivo has been demonstrated by 
several groups [29,30,227]. Tax-mediated NF-B activation stimulates a number of cytokines and their 
corresponding receptors such as IL-2/IL-2R, IL-9, IL-13, IL-15/IL-15R, IL-21/IL-21R, IL-8, CCL2, 
CCL5, CCL22, CCR9, CXCR7, CD40, OX40/OX40L and 4-1BB/4-1BBL [228-245]. Approaches to 
block NFB using drugs or peptide inhibitors have resulted in tumor cell regression in animal models 
[227].  
8.3. Tax and pathogenesis 
Tax has two main functions in the pathogenesis of HTLV-1. First is constitutive cell cycle 
progression and the second is resistance to apoptosis. Tax induces cell cycle progression by protein-
protein interaction and transcriptional regulation of cell cycle-associated proteins. Specifically, Tax 
stimulates the transition of cells from G1 to S phase through the hyper-phosphorylation of Rb and 
activation of E2F transcription factors and by the induction of cyclin D2 and cyclin-dependent kinase 6 
(CDK6) via the NF-B pathway (both classical and alternate). In addition, Tax activates CDK4/CDK6 
through the direct interaction with CDK4, CDK6 and CDK inhibitors like CDKN1A, p16
INK4A and 
p15
INK4B [246-255]. Thus, Tax induces the expression of cell cycle regulators in an NF-B-dependent 
manner and subsequently activates them in an NF-B-independent manner. Tax also influences Viruses 2010, 2                  
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transformation and regulates apoptosis in T cells by activation of the phosphatidyl inositol 3 kinase 
(PI3K)/Akt pathway. Mechanistically, Tax frees a catalytic p110 subunit of the PI3K complex from 
an inhibitory p85 subunit by binding directly to the latter [256]; Tax induces the RelA-mediated 
sequestration of p300 from the promoters of phosphatase and tensin homolog (PTEN) and SH2 
domain-containing inositol phosphatase - 1 (SHIP-1), thereby down-regulating their expression [257]; 
Tax influences a number of factors that affect the PI3K/Akt pathway including mammalian target of 
rapamycin (mTOR), AP-1, NF-B, CREB/ATF, β-catenin, and hypoxia inducible factor – 1 (HIF-1) 
[256,258-261]. Tax induces anti-apoptotic proteins such as Bcl-xL, survivin, cFLIP, xIAP, cIAP1 and 
cIAP2 in an NF-B-dependent manner [262-267]. Both the classical and alternative NF-B pathways 
play a positive role in the inhibition of apoptosis in HTLV-1-infected T cells.  
Tax exhibits its oncogenic potential by both clastogenic DNA damage and aneuploidic effects 
[112,184,268,269]. Tax promotes clastogenic DNA damage by repressing the expression of DNA 
polymerase β, which is involved in base excision repair, nucleotide excision repair, and repression of 
human telomerase reverse transcriptase (hTERT), thus subverting Ku80 activity (a protein essential for 
DNA repair) [269]. All of these mechanisms result in reduced protection from double stranded DNA 
breaks as well as telomere extension, which could be the reason for end-to-end fusion of chromosomes 
observed in HTLV-1-infected cells. During DNA damage, the complex DNA damage response (DDR) 
signaling molecules such as ATM, ATR and DNA-PK kinases become activated and orchestrate DNA 
repair [268,270,271]. Tax can induce checkpoint activation and cell cycle arrest at the G1 phase by 
inducing p27/kip1 and p21/waf1 [272]. This function of Tax appears to be paradoxical to its 
transforming activity. Nevertheless, the constitutive activation of the DDR pathway and the checkpoint 
adaptation facilitating the proliferation of T cells with DNA damage causes genetic instability and 
ultimately evolution of ATL clones. Tax causes aneuploidy by interacting with proteins that monitor 
chromosomal segregation during mitosis through the following mechanisms: induction of 
supernumerary centrosomes and multipolar mitosis via interactions with Tax-1 binding protein-2 
(TAX1BP2) and Ran/TC4-binding protein (RanBP1); unscheduled degradation of securin and cyclin 
B1 by interacting with CDC20-associated anaphase-promoting complex (APC); and impairment of 
mitotic spindle assembly checkpoint protein 1 (MAD1) activity, an integral function of the mitotic 
spindle assembly checkpoint (SAC) [112]. Tax also plays a key role in promoting oncogenesis by 
abrogating the function of the tumor suppressor gene, p53. The biological activity of p53 is central to 
the integrity of a cell in that any loss of its function either due to mutation or inactivation increases the 
chance of genetic instability leading to oncogenesis. The subcellular localization and phosphorylation 
status of p53 are critical for its function. In a majority of HTLV-1 infected cell lines, p53 function is 
impaired although the protein itself is sufficiently expressed and stable. Two mechanisms have been 
identified for the abrogation of p53 function by Tax. First, it was demonstrated that the expression of 
Tax-1 or Tax-2 impaired the functionally relevant phosphorylation of p53 at serines 15 and 392; Tax 
activation of the NF-B pathway was essential for this activity [273,274]. Second, it was demonstrated 
that Tax competes with p53 for the binding with CBP/p300, which results in the decreased ability of 
p53 to activate cell cycle control genes [275,276].  
A PDZ binding motif (PBM) or domain, which is comprised of a four amino acid sequence at the 
C-terminus of HTLV-1 Tax, has been implicated in T cell proliferation and transformation. The PDZ 
domain is named after the first identified PDZ-containing proteins, post-synaptic density protein   Viruses 2010, 2                  
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(PSD-95),  Drosophila discs large protein (DLG) and epithelial tight junction protein (Zonula 
Occludens-1). The PDZ domain is commonly used in eukaryotic cells to recruit and organize proteins 
to sites of cellular signaling. Using both virus gene knockout and knockin approaches, Xie et al. 
investigated the role of the Tax PBM in both cell culture and infected animals. These authors 
demonstrated that the PBM of HTLV-1 Tax significantly increased HTLV-1-induced primary T cell 
proliferation in vitro. Moreover, HTLV-1 proviruses containing a deletion in this four amino acid 
motif had severely attenuated infectivity and persistence in vivo [277]. HTLV-2 Tax does not contain 
this PBM domain. Interestingly, a chimeric HTLV-2 virus containing the HTLV-1 Tax PBM 
significantly increased primary human T cell proliferation in vitro, thus lending further support that 
this domain plays a key role in Tax pathogenic activity[277]. The three PDZ-containing proteins in 
humans are hDLG, membrane associated guanylate kinase (MAGUK) with inverted orientation – 3 
(MAGI-3) and precursor of interleukin–16 (pro-IL-16), all of which have been implicated in tumor 
suppression or cell cycle regulation, and have been demonstrated to interact with Tax PBM [278-281]. 
HTLV-1 Tax PBM competes with the adenomatous polyposis coli (APC) tumor suppressor protein for 
the hDLG binding domain [282]; PBM competes with another tumor suppressor, phosphatase with 
tensin homology mutated in multiple advanced cancers (PTEN/MMAC) for binding to MAGI-3 [283]; 
and PBM also interacts with the first PDZ domain of pro-IL-16 [280], all of which result in the 
reversal of cell cycle arrest in G0/G1 phase induced by hDLG. Using a panel of Tax-1 and Tax-2 
mutants, the PBM has been demonstrated to enhance micronuclei induction in transfected cells, which 
probably plays a role in the genomic instability caused by Tax [277,284,285]. PBM also has been 
shown in other oncogenic viruses including human papillomavirus and adenovirus, which points 
toward a possible mechanism for PBM and PDZ-containing proteins in cellular transformation and 
pathogenesis by tumorigenic viruses [209,286,287].  
9. Role of HBZ in HTLV-1-induced oncogenesis 
HBZ is encoded by an mRNA transcribed from the minus strand of the proviral genome. 
Transcription from the antisense strand of HTLV-1 was first reported in 1989 [288]. Almost a decade 
later, the viral protein HBZ was detected in HTLV-1 transformed cell lines. HBZ was identified as a 
binding partner of CREB-2 by yeast two-hybrid assays [41]. Hbz transcription is driven by a TATA-
less promoter in the 3ʹ end of the proviral genome activated primarily by Sp1 [289]. HBZ is expressed 
from three mRNA transcripts, unspliced form (usHbz) and two spliced forms (sHbz) – major and 
minor, as identified by 5ʹ rapid amplification of cDNA ends (RACE) [46,290,291]. The sHbz 
transcripts have multiple initiation sites in the unique 5ʹ (U5) and R regions of the 3ʹLTR, whereas the 
usHbz initiates from within the tax gene. The TxRE in the 3ʹLTR functions as the promoter enhancer 
element for Hbz transcription, although its function is much weaker compared to the 5ʹLTR TxRE 
[289,292]. This provides one explanation why the gene expression of tax and Hbz are inversely 
proportional during the course of HTLV-1 infection and disease progression. There are marked 
differences between the unspliced and spliced HBZ isoforms both at the RNA and protein levels 
(Table 1). Hbz transcripts are expressed at relatively constant levels in ATL cells, regardless of the tax 
expression levels [293]. Total Hbz transcripts detected in an infected individual are directly 
proportional to the proviral load, probably due to their dependence on Sp1 for transcription [46]. The Viruses 2010, 2                  
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difference between sHbz and usHbz transcripts is the presence of the first exon in the former. This 
region corresponds to a small portion of the Rex-responsive element (RxRE) in the sense strand. In the 
antisense strand, this region forms a variable stem loop structure that might interact with host factors to 
induce the proliferation of ATL cells in an IL-2-independent manner [46,289]. Saito et al. have 
reported a correlation between the Hbz transcript levels and the severity of HAM/TSP, which suggests 
a possible role for HBZ in the pathogenesis of HAM/TSP [293]. 
Table 1. Structural and functional differences between the unspliced and spliced Hbz. 
Structure/Function usHBZ  sHBZ 
RNA    
Transcription initiation site [47,293,294]  Within the tax gene  Multiple sites in the U5 
and R region of the 3ʹLTR 
Weak promoter enhancement by TxRE 
[47,293,294]
  
? Yes 
mRNA transcription efficiency 
[47,293,294] 
0.25X 1X 
Promotes T cell proliferation [46,289]   Weak  Strong 
Protein    
Half-life of the protein [47,293,294]  Short  Long 
Detection levels in ATL cell lines and 
HTLV-1 infected cells 
Low High 
Inhibition of AP-1 transcription [42,45]   Weak  Strong 
Delivery of c-Jun to proteasomal 
degradation [42,45]  
 
Strong Weak 
Western blot analyses have shown the expression of sHBZ protein in almost all ATL cell lines. The 
HBZ protein contains three domains – activation, central and basic leucine zipper (bZIP) [41,295]. 
HBZ binds to cellular factors like c-Jun, JunB, JunD, CREB-2 and CREB via the bZIP   
domain [41,42,44]. The bZIP and the activation domains are involved in the activation of JunD [45], 
increase of hTERT [296] and the binding with the p65 subunit of NF-B [297], thereby inhibiting the 
classical pathway of NF-B activation. HBZ protein has been shown to localize in the nucleoli with a 
speckled staining pattern by immunohistochemistry. The integrity of the amino acid sequence of HBZ 
must be maintained for this speckled pattern to be observed [295]. This nuclear localization signal is 
located in the central domain and is comprised of three regions: two regions rich in basic amino acids 
and one DNA binding domain. HBZ interacts with the CBP/p300 KIX domain and the 26S proteasome 
through the activation domain [298]. HBZ interacts with CREB-2 (ATF-4) through the bZIP domain, 
which abolishes the binding of CREB-2 to TxRE in the 5ʹLTR and, in turn, results in the down-Viruses 2010, 2                  
 
 
2050
regulation of Tax-mediated viral transcription in an HBZ dose-dependent manner [41,299]. HBZ 
inhibits the transcriptional activity of cellular factors by localizing in the heterochromatin and also by 
sequestering JunB into nuclear bodies [300,301]. HBZ disrupts the basal transcription of both HTLV-1 
and cellular promoters by attenuation of AP-1 activation (Fos/Jun dimers) via degradation of c-Jun in a 
ubiquitination-independent manner and also by directly interacting with the 26S proteasome, thereby 
causing proteasomal degradation of c-Jun [42,45]. In addition, HBZ interacts with JunD to activate 
cellular genes including hTERT, which activates the telomerase in cell mitosis, a critical late event in 
tumor progression that indicates a role for HBZ in the development and maintenance of leukemic cells 
[296]. It is interesting to note that JunD is primarily a growth suppressor that functions by interacting 
with the tumor suppressor, menin [302]. However, in the presence of HBZ, JunD forms homodimers 
with HBZ and thereby increases its transcriptional and transforming activity. Recently, both isoforms 
of HBZ have been shown to hetero-dimerize with MafB via their bZIP domains and abrogate the DNA 
binding activity of MafB. MafB is a transcriptional factor that is responsible for lineage-specific 
hematopoiesis. Additional investigations are required to delineate the effect of this suppression [303]. 
HBZ and pathogenesis 
Although no antibody responses against HBZ have been detected so far from HTLV-1-infected 
carriers [304], recent evidence has shown that HBZ is immunogenic in vitro. When exposed to DCs, 
HBZ was processed and presented in the context of HLA-A*0201. HBZ peptides induced specific 
cytotoxic T lymphocytes (CTL), but they failed to lyse HLA-A*0201-positive HTLV-1-infected T cell 
lines and ATL cells. This could be because the amount of HBZ protein expressed by HTLV-1 infected 
cells is not sufficient to be recognized by the HBZ-specific CTLs. HBZ-specific CTLs are detected in 
very sparse numbers in ATL patients and healthy carriers [305]. 
Kinetic analyses of gene expression levels in HTLV-1 proviral plasmid over-expression studies in 
cell culture revealed that Hbz mRNA levels are significantly lower than tax/rex mRNA levels [306]. In 
the context of an infectious molecular clone, like other accessory gene products, Hbz was dispensable 
for immortalization of primary human T cells in vitro. Stable T cell clones generated with Hbz 
defective proviruses produced significantly higher levels of p19 Gag protein indicating increased Tax-
mediated viral gene expression [307]. Stable HBZ expression promoted the IL-2-independent survival 
of Kit-225 cells (a leukemic T cell line that is solely dependent on exogenous IL-2 for survival) [46] 
and increased the proliferation of Jurkat T cells [47]. Knockdown of HBZ expression by shRNA 
decreased cell proliferation in ATL cell lines, HTLV-1 transformed cell lines, and newly immortalized 
primary T cells [47]. Hbz RNA, specifically a stem loop structure near the amino terminus of the 
transcript, and not the protein, increased T cell proliferation by increasing the transcription of the 
E2F1 gene [46]. HBZ binds to the Rel homology domain of the p65 subunit of NF-B and degrades 
p65, thus inhibiting the classical NF-B pathway. This function is mechanistically tailored by the 
increase of E3 ubiquitin ligase, PDLIM2 (PDZ and LIM domain containing protein 2) [297,308].  
NF-B functions through a classical and an alternate pathway and both have distinct regulatory 
functions. The alternate pathway is critical for cellular transformation, while both the pathways 
regulate anti-apoptotic genes differentially in lymphoma cell lines. HBZ enhances the expression of Viruses 2010, 2                  
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PDLIM2, which suppresses Tax-mediated tumorigenicity by promoting the degradation of Tax. Thus, 
HBZ suppresses Tax both at the RNA and protein levels. 
Recently, Polakowski et al. have demonstrated that siRNA-mediated knockdown of CBP/p300 or a 
truncated form of CBP/p300 containing the KIX domain abrogated the expression of Dickkopf-1 
(Dkk-1), a Wnt signaling inhibitor in HBZ transfected cells [309]. Dkk-1 has been shown to play an 
important role in the development of bone lesions in multiple myeloma. Lytic bone lesions are also a 
symptom of ATL. DKK-1 mRNA levels were positively correlated with the expression of Hbz in 
HTLV-1 infected cell lines. Interestingly, Tax represses the expression of Dkk-1 consistent with the 
opposing forces of Tax and Hbz within the cell. Taken together, in the late stages of ATL, when Tax is 
repressed, HBZ supports cell proliferation and the maintenance of the leukemic cell.  
In vivo studies in rabbits revealed a significant reduction in proviral load and attenuated antibody 
response against the viral proteins correlating with the loss of HBZ function [299]. Proviral load was 
decreased by 5-to-50-fold as early as two weeks post infection in these animals. Kinetic analyses of 
viral gene expression confirmed the in vitro data that Hbz mRNA levels were low early after infection 
and then increased to a stable plateau. This trend was similar to that of the proviral loads and was the 
reverse of the tax/rex mRNA levels [307]. Thus, HBZ plays an important function in viral persistence. 
There was an increase in CD4
+ T cells in the spleens of transgenic mice expressing HBZ under the 
control of the mouse CD4 promoter/enhancer [46]. Another study with NOD/SCID
chain-/- mice showed 
that HBZ knockdown in a transformed T cell line significantly reduced tumor formation and organ 
infiltration [47]. Together, these two studies confirm that HBZ is essential for promoting T cell 
proliferation. 
10. Combined mechanisms of Tax and HBZ in HTLV-1-induced oncogenesis 
A number of mechanisms involving Tax and HBZ have been demonstrated to play a role in   
HTLV-1-induced oncogenesis (Figure 2). Tax is indispensable for the transformation process induced 
in HTLV-1 infected cells. However, once transformed, these cells do not require Tax to maintain their 
leukemic state [184,310]. Tax is detected only in about 40% of ATL patients [311]. In approximately 
10% of ATL cases, genetic changes in tax have been documented; DNA methylation of tax has been 
shown in another 15% of ATL patients; and deletion of the 5ʹLTR and promoter region has been 
shown in an additional 27% of ATL cases [311-316]. In addition, p30 has been shown to repress viral 
replication at the post-transcriptional level by binding to and retaining tax/rex mRNA in the nucleus 
[38,103]. By suppressing Tax protein expression, p30 attenuates HTLV-1 transcription. More recently, 
it was reported that p30 and the positive post-transcriptional regulator Rex form ribonucleoprotein 
complexes specifically on tax/rex mRNA [317]. Together, these data suggest that p30 may govern the 
switch between viral latency and replication. 
In HTLV-1, the 3ʹLTR is identical to the 5ʹLTR. Both carry the TxRE sequences that have the 
enhancer elements for transcription. However, the enhancing elements of the antisense transcript are 
much weaker than the sense transcript. This could be part of the reason why Hbz is detected during the 
later stages of HTLV infection, unlike tax/rex and gag/pol, which are expressed at high levels during 
the early stages of infection. Expression of HBZ is correlated positively with proviral loads and 
negatively with tax/rex and gag/pol expression [307]. HBZ expression also is correlated positively Viruses 2010, 2                  
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with disease severity in ATL and HAM/TSP, suggesting a role in pathogenesis [46,293]. HBZ was 
detected in all ATL cells, including those that lacked Tax expression. As mentioned above, the 
absence of Tax in these cells is attributed to genetic changes in the tax gene and/or the 5ʹLTR. Neither 
the Hbz gene nor the 3ʹLTR are affected by any of these epigenetic silencing mechanisms. Miyazaki et 
al. showed that in one ATL case, the polyadenylation site of Hbz gene was deleted. However, the Hbz 
gene utilized a downstream polyadenylation signal for transcription [316].  
Tax initially increases hTERT expression facilitating lifespan extension and immortalization of 
cells. Once the virus establishes persistence, Tax represses hTERT via an E-box present in the hTERT 
promoter probably through competition for CBP/p300, and thus favors accumulation of chromosomal 
rearrangements and then the transformation of the infected cells towards a malignant phenotype. 
Subsequent epigenetic silencing of Tax in the leukemic cells reactivates hTERT, which in turn, 
stimulates the proliferative potential of the infected cells leading to ATL. The reactivation of hTERT is 
a key event in the induction of ATL progression, which is probably tailored by HBZ [302]. 
Another possible mechanism that could cause epigenetic silencing has been elucidated recently by 
Fan et al. [318]. They showed that HTLV-1 is prone to RNA editing by human APOBEC3G during 
reverse transcription, although the editing is at a low frequency. The authors have attributed the 
nonsense mutations in the plus strand of the proviral DNA coding for env, tax, p13 and p30 to be 
responsible for the reduced viral gene expression in these cells. The generation of nonsense mutations 
does not affect the Hbz gene, which codes from the minus strand. Moreover, there are very few 
mutation sites in the opposite strand of the HBZ coding region. Therefore, the functional activity of 
HBZ is not affected. It also was shown that these mutations occur both in ATL cells and HTLV-1 
infected cells from asymptomatic carriers, indicating that these mutations do not occur during 
oncogenesis but are present even during the carrier state. The mutations were present in the leukemic 
cells and not in the non-leukemic HTLV-1 infected cells, suggesting that there is a selection for these 
cells during leukemogenesis, which likely favors the virus by promoting immune evasion [318]. 
Evidence from another group suggests that the 5ʹLTR deletion occurred before integration in 8/12 ATL 
cases and after integration in 4/12 ATL cases. This deletion was detected in 3.9% of the carriers and in 
27.8% of ATL patients. In these defective proviruses, the second exons of the tax, rex and p30 genes 
were frequently deleted, and thus Tax-mediated activation of NF-B and CREB pathways was 
abrogated. In all these cases, the coding sequences of the Hbz gene were intact [316].  
Taken together, the possible mechanism of HTLV-1-induced oncogenesis suggests that Tax is 
expressed initially to induce transformation and cell proliferation. Tax-specific CTLs mediate the 
death of virus infected cells. Thus, the virus is forced to down-regulate Tax expression to below 
detectable levels by the expression of HBZ in order to persist in the host. Since HBZ-specific CTLs do 
not lyse ATL cells and HBZ can promote and maintain the leukemic state of these cells, this 
mechanism ought to be favored by the virus in order to evade immune surveillance and continue to 
persist in the host. However, why it would be in the best interest of the virus to cause cancer, which is 
a dead end situation for itself, although in a very small percentage of infected individuals, is still an 
unanswered question. 
 Viruses 2010, 2                  
 
 
2053
Figure 2. A schematic model illustrating the possible mechanisms by which HTLV-1 succumbs to and 
evades the host immune system. The sequence of events is labeled with Arabic numerals. 1: attachment and 
entry of a virion into a target cell; 2: the capsid uncoats releasing the viral RNA; 3: low frequency editing of the 
genomic RNA by APOBEC3G, one possible mechanism for epigenetic silencing; 4: reverse transcription into 
double-stranded DNA; 5: proviral integration into the host chromosome; 6: initial transcription and export of 
completely/doubly spliced viral mRNA by host cellular factors; 7: favorable translation of Tax due to a strong 
Kozak sequence; 8: Tax transactivation of the viral LTR to promote viral gene expression; 9: Tax increases 
cellular transcription, promotes DNA damage, regulates cell cycle and induces proliferation of genetically 
altered cells. Tax also increases hTERT function initially to induce transformation of virus infected cells, but 
subsequently down-modulates hTERT to accumulate chromosomal rearrangements and maintain 
transformation; 10: high expression of Tax by virus infected cells results in their elimination by Tax-specific 
CTL induced cell death; 11: expression of viral accessory proteins like p12 and p13 facilitates viral persistence 
in the host. Additionally, the sparsely elicited HBZ-specific CTLs do not lyse ATL cells due to the low HBZ 
protein expression levels in all ATL cell lines and HTLV-1 transformed cell lines. This helps in immune evasion 
and viral persistence; 12: the accessory protein, p30, translocates to the nucleus and forms ribonucleoprotein 
complexes with Rex to retain tax/rex mRNA in the nucleus, and thus represses the expression of Tax; 13: HBZ 
represses Tax at the transcriptional level by competing for CREB-2 and CBP/p300, and at the protein level by 
enhancing the expression of PDLIM2. Furthermore, HBZ complements for the reduced activity of Tax by 
activating cellular factors to induce transformation and proliferation of genetically unstable cells; 14:epigenetic 
silencing mechanisms also result in decreased Tax expression levels facilitating viral persistence; 15: reduced 
Tax and increased HBZ levels reactivate hTERT, which is a key event in the progression of ATL.   
 Viruses 2010, 2                  
 
 
2054
11. Conclusions  
HTLVs are complex retroviruses with unique proteins that have oncogenic potential. There are four 
known strains of HTLV, HTLV-1, HTLV-2, HTLV-3, HTLV-4; only HTLV-1 and HTLV-2 have been 
consistently associated with disease in humans. HTLV-1 mainly causes ATL and HAM/TSP. HTLV-2 
is not etiologically oncogenic and has been associated with some neurological disorders. HTLV-3 and 
HTLV-4 were identified in African primate hunters without any subsequent etiological disease 
associations so far.  
A complete understanding of the functions of the viral genes would give insights into the 
pathogenic mechanisms by which HTLV-1 induces oncogenesis. In this review we summarize the data 
published so far in this field with pertinent comparisons to HTLV-2, the non-leukemic counterpart. 
Like simple retroviruses, HTLV-1 expresses structural and enzymatic proteins for its assembly and 
maturation, and for entry into new target cells. HTLV-1 also expresses regulatory and accessory 
proteins that are essential for viral persistence, immune evasion and ultimately, leukemogenesis. 
Although, the exact mechanisms and pathways have not been fully elucidated, much is known thus far. 
For instance, Tax is expressed in the early stages of infection to establish viral transcription and induce 
T cell transformation by regulating cellular transcription factors, inducing G1 to S phase transition and 
DNA damage resulting in genetic instability, and promoting proliferation of genetically altered 
(leukemic) cells. Subsequently, HBZ suppresses Tax expression to evade immune elimination by Tax-
specific CTLs, and also complements for Tax to support proliferation; it provides a second oncogenic 
signal required for the maintenance of the leukemic cell. Further investigations are warranted to 
determine the additional events in the minor population that progresses to ATL. 
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